BACKGROUND: Both patient- and physician-related factors have been shown to explain variability in the outcomes of antihypertensive treatment. Total cardiovascular risk (TCVR) is increasingly used as a ...

This study's principal finding that second-line treatment with a regimen that includes SPC amlodipine/valsartan formulations reduces BP, increases BP control, and improves TCVR status is critical in ...